From our results in eight patients with lung cancer, we concluded that, rather unexpectedly, CD3+CD8+ T cell-excluded tumors express TAAs more abundantly and they have a higher presentation efficiency of TAAs. The gene discussed is CD8A; the disease is lung cancer.